Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 18/20 | 1.00 |
| ▸ | TERT | O14746 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16540376 | 0.90 | MCL1 (1.00) | MCL1TERTBAD | |
| SCHEMBL16540443 | 0.88 | MCL1 (1.00) | MCL1BAD | |
| SCHEMBL16540567 | 0.87 | MCL1 (1.00) | MCL1 | |
| SCHEMBL16540533 | 0.85 | MCL1 (1.00) | MCL1TERT | |
| SCHEMBL16540728 | 0.81 | MCL1 (1.00) | MCL1TERTBAD | |
| SCHEMBL16549716 | 0.80 | MCL1 (1.00) | MCL1TERT | |
| SCHEMBL16540084 | 0.79 | MCL1 (1.00) | MCL1TERTBAD | |
| SCHEMBL16540454 | 0.79 | MCL1 (1.00) | MCL1TERT | |
| SCHEMBL16549717 | 0.76 | MCL1 (1.00) | MCL1 | |
| SCHEMBL16539921 | 0.76 | MCL1 (1.00) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3038618-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3038618-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| EP-3038618-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015031608-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015031608-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | MCL1 137/4885TERT 25/4885PTGDR2 2928/4885 |
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | MCL1 1/4885TERT 1233/4885PTGDR2 2165/4885 |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | MCL1 1/4885TERT 1233/4885PTGDR2 2165/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | MCL1 8/4885TERT 10/4885PTGDR2 2531/4885 |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | MCL1 1/4885TERT 1233/4885PTGDR2 2165/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | MCL1 1/4885TERT 1233/4885PTGDR2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.